How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're fortunate enough to have $10,000 sitting in your savings account and no immediate use for it, then it could be worth putting it to work in the share market.

After all, with a historic return in the region of 10%, that $10,000 could become $11,000 in 12 months if history were to repeat itself.

In addition, if you can find an ASX share with market-beating potential, then you could grow your wealth even more.

But which shares could do this? Could CSL Ltd (ASX: CSL) shares beat the market? Let's find out.

A man thinks very carefully about his money and investments.

Image source: Getty Images

$10,000 invested in CSL shares

At present, the CSL share price is trading at $289.24. This means that if you were to invest $10,000 (and a further $123.40), you would end up owning 35 units.

According to a recent note out of Morgans, its analysts see scope for the company's shares to rise from current levels. The broker said:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Morgans has an add rating and $315.35 price target on CSL's shares. This implies potential upside of 9% and values those 35 units at $11,037.25.

Bigger returns

The good news is that even bigger returns could be on the cards according to analysts at Macquarie.

A recent note out of the investment bank reveals that its analysts have an outperform rating and $330.00 price target on the company's shares. This suggests that upside of 14.1% is possible over the next 12 months.

If this recommendation proves accurate, those 35 CSL shares would have a market value of $11,550. That's almost $1,500 greater than your original investment.

But it gets better. Macquarie is feeling very positive about the outlook of the CSL Behring business. This is particularly important given how it is far and away the biggest contributor to CSL's overall earnings.

As a result, the broker sees scope for CSL's shares to rise significantly over the next three years thanks to the strength of the CSL Behring business. So much so, it believes that a share price of $500 is possible by 2027.

If that happens, it would mean those 35 shares will be worth a sizeable $17,500. That's a very large increase on the original outlay of $10,123.40.

Here's hoping that Macquarie is on the money with its recommendation and valuation.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Regis Healthcare expects FY26 EBITDA to hit top end of guidance

Regis Healthcare expects top-end FY26 earnings as strong occupancy, RAD inflows, and efficiency gains set a positive outlook.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

This ASX healthcare stock could be set to rise 50%

This small cap could be one to watch.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Up 60%: Why this exciting ASX stock could keep rising

This speculative stock could still have significant upside according to Bell Potter.

Read more »